Clinical Review Criteria 4Kscore@ Test: Predicting the Risk of Aggressive Prostate Cancer
Clinical review criteria for the 4Kscore (four kallikrein marker) blood test to predict risk of high-grade/aggressive prostate cancer for Kaiser Foundation Health Plan of Washington members; includes Medicare and non-Medicare guidance, background, evidence appraisal, and code-level coverage determination.
Removed Medicare LCD L37122 (retired 6/12/22) and LCA A57337 and added KPWA Medical Policy statement under Medicare section.
Added Medicare instructions and CPT code 81539 on 10/10/2017; subsequent removals and edits noted in revision history.
No material clinical or coverage changes identified in this update.
Coverage Summary
Scope: Clinical review criteria for the 4Kscore Test — a blood-based four kallikrein marker panel to predict risk of high-grade/aggressive prostate cancer for Kaiser Foundation Health Plan of Washington members, including Medicare and non‑Medicare guidance.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.